A multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of CS-917 [Daiichi Sankyo Inc] as monotherapy for type 2 diabetes

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of CS-917 [Daiichi Sankyo Inc] as monotherapy for type 2 diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs CS 917 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 02 Aug 2007 Status changed from in progress to completed.
    • 05 Feb 2007 Status change
    • 01 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top